Ceramide in Stress Response

Mariana N. Nikolova-Karakashian* and Krassimira A. Rozenova

Abstract

Evidence has consistently indicated that activation of sphingomyelinases and/or ceramide synthases and the resulting accumulation of ceramide mediate cellular responses to stressors such as lipopolysaccharide, interleukin 1β, tumor necrosis factor α, serum deprivation, irradiation and various antitumor treatments. Recent studies had identified the genes encoding most of the enzymes responsible for the generation of ceramide and ongoing research is aimed at characterizing their individual functions in cellular response to stress. This chapter discusses the seminal and more recent discoveries in regards to the pathways responsible for the accumulation of ceramide during stress and the mechanisms by which ceramide affects cell functions. The former group includes the roles of neutral sphingomyelinase 2, serine palmitoyltransferase, ceramide synthases, as well as the secretory and endosomal/lysosomal forms of acid sphingomyelinase. The latter summarizes the mechanisms by which ceramide activate its direct targets, PKCε, PP2A and cathepsin D. The ability of ceramide to affect membrane organization is discussed in the light of its relevance to cell signaling. Emerging evidence to support the previously assumed notion that ceramide acts in a strictly structure-specific manner are also included. These findings are described in the context of several physiological and pathophysiological conditions, namely septic shock, obesity-induced insulin resistance, aging and apoptosis of tumor cells in response to radiation and chemotherapy.

Introduction

Cells and organisms have developed various strategies to deal with adverse changes in their environment. Cellular insult by infectious agents, toxins, nutrient deprivation, or genotoxic stress produces a coordinated systemic response (generally referred to as inflammation), which is aimed at neutralization of the insult and initiation of tissue repair. The first line of defense at systemic level is stimulation of the innate immune response, which consists of regulated production of inflammatory mediators, including cytokines like IL-1β, TNFα and IL-6. The typical cellular response to environmental stressors includes the induction of cellular apoptosis (in response to either genotoxic stress or cytokines like TNFα), growth arrest (during nutrient deprivation), increased eicosanoid production, cell migration and adhesion (in the presence of infectious agent). While acute inflammation is protective for the organisms, excessive and long-standing inflammation is harmful and underlies diseases like septic shock, atherosclerosis, asthma, rheumatoid arthritis and inflammatory bowel disease.

Diverse signaling pathways mediate cellular response to stress. The sphingolipid second messengers ceramide, ceramide-1-phosphate, sphingosine and sphingosine-1-phosphate play important role as mediators in many of these pathways. This chapter is focused on the role of ceramide in cellular stress response and the mechanisms of its generation and action.

*Corresponding Author: Mariana N. Nikolova-Karakashian—Department of Physiology, University of Kentucky College of Medicine, Lexington, Kentucky 40536. Email: mnikolo@uky.edu

Sphingolipids as Signaling and Regulatory Molecules, edited by Charles Chalfant and Maurizio Del Poeta. ©2010 Landes Bioscience and Springer Science+Business Media.
Chemical Structure and Biophysical Properties of Ceramide

Ceramides (Fig. 1) form the hydrophobic backbone of all complex sphingolipids and consist of a long chain sphingoid base and amid linked fatty acid which is either saturated or unsaturated and vary in length from two to 28 carbon atoms. In mammalian cells, the most commonly found ceramides have D-erythro-sphingosine and a saturated fatty acyl chain of 16 carbon atoms and are among the most hydrophobic lipids in the membrane. Free ceramide has a very low critical micellar concentration (cmc < 10^{-10}M) and cannot exist in aqueous solutions. Nevertheless, ceramides are still considered as amphiphiles because the hydroxyl group at the first carbon and the amide bond are hydrophilic moieties. Dihydroceramide differs from ceramide inasmuch as the latter contains a trans 4, 5 double bond, which is essential for some of the bioactive roles of ceramide.

The structural features in the ceramide molecule that are required for its biological properties are not well understood, however the two hydroxyl groups, amid group protons and the trans-double bond seems to be involved. A network of intramolecular hydrogen bonds involving the OH and NH groups establishes a unique conformation arrangement of ceramide molecule.

Changes in Ceramide Mass during Stress

The basal ceramide concentrations in the cells are low and may change during cellular differentiation or progression through the cell cycle. Various inducers of cellular stress however lead to an accumulation of ceramide that promotes apoptotic, inflammatory and growth inhibitory signals and also mediates the onset of a specific response. The data in Table 1 illustrate what is the magnitude of changes in ceramide levels under various conditions of stress. These reported differences however, are likely to be an underestimation since they are measured in total cell preparations and not in the specific membrane fractions where ceramide was generated. Furthermore, with the exception of mass spectrometry—based assays, the most commonly used methods of ceramide quantification do not separate the individual ceramide species. This might be important as the impact ceramide has on cell functions seemingly depends on the type of fatty acid attached to the sphingoid base. Recent data indeed support the notion that the different biological effects caused by ceramide may be mediated by distinct molecular species of the lipid, underscoring the necessity to evaluate changes in ceramide content in a structure-specific manner.

A comparison of the magnitudes of ceramide accumulation observed under various treatments reveals that the changes are more robust in response to chemotherapeutics or irradiation. As the outcome of these treatments has been the induction of cell death via apoptosis, some investigators...
### Table 1. Changes in ceramide content in response to stress and during some pathophysiological conditions

| Condition       | Control     | Treatment       | Assay   | Tissue/Cell Type     | Ref. |
|-----------------|-------------|-----------------|---------|----------------------|------|
| Hypoxia/Re-     | 4.5 pmol/nmol LP | 8.5 pmol/nmol LP | Mass Spec | NT-2                 | 6    |
| oxygenation     | 100%        | 200% of control | DAGK    | Cardiac myocytes     | 7    |
|                 | 22 pmol/nmol LP | 55 pmol/nmol LP | DAGK    | NRK-52E              | 8    |
|                 | 250 pmol/mg Pr | 900 pmol/mg Pr  | DAGK    | PC-12                | 9    |
|                 | 100%        | 300% of control | DAGK    | HUVEC                | 10   |
|                 | 100%        | 50% of control  | DAGK    | A7r5                 | 11   |
| Ischemia/Re-    | 110% of sham | 175% of sham    | Mass Spec | Brain               | 12   |
| Reperfusion     | 50 pmol/nmol | 290 pmol/nmol LP | DAGK    | Rat cardiomyocytes   | 13   |
|                 | 190 pmol/mg Pr | 290 pmol/mg Pr  | DAGK    | Renal cortex         | 14   |
|                 | 100%        | 300% of control | DAGK    | Liver                | 15   |
| IL-1β           | 100%        | 390% of control | DAGK    | Rat astrocytes       | 16   |
|                 | 100%        | 170% of control | DAGK    | CG-4                 | 17   |
|                 | 18 pmol/nmol LP | 45 pmol/nmol LP | DAGK    | Rat myocytes         | 18   |
|                 | 75 cpm/10^6 cells | 160 cpm/10^6 cells | Labeling | Rat mesangial cells | 19   |
|                 | 1 nmol/mg Pr | 1.5 nmol/mg Pr | HPLC    | Rat hepatocytes      | 20   |
|                 | 1.1 nmol/mg Pr | 1.48 nmol/mg Pr | HPLC    | Rat hepatocytes      | 21   |
|                 | 250 pmol/10^6 cells | 500 pmol/10^6 cells | DAGK    | HUVEC                | 22   |
|                 | 450 pmol/10^6 cells | 800 pmol/10^6 cells | DAGK    | Dendritic cells      | 23   |
|                 | 100%        | 170% of control | Labeling | Thyroid cells        | 24   |
| TNF-α           | 100%        | 150% of control | HPLC    | Cortical neurons     | 25   |
|                 | 100%        | 300% of control | DAGK    | Rat astrocytes       | 16   |
|                 | 200 pmol/mg Pr | 850 pmol/mg Pr  | DAGK    | U-87 MG cells        | 26   |
|                 | 22 pmol/10^6 cells | 37 pmol/10^6 cells | DAGK    | Mesangial cells      | 27   |
|                 | 100%        | 300% of control | HPLC    | Hepatocytes          | 28   |
|                 | 0.8 nmol/mg Pr | 1.4 nmol/mg Pr  | DAGK    | Lung microsomes      | 29   |
|                 | 5.0 nmol/mg Pr | 10.9 nmol/mg Pr | HPLC    | Alveolar lavage      | 30   |
|                 | 0.5 nmol/nmol LP | 1.1 nmol/nmol LP | Mass Spec | Endothelial cells    | 31   |
|                 | 100%        | 400% of control | DAGK    | MIN6 cells           | 32   |
|                 | 100%        | 700% of control | DAGK    | MCF-7 cells          | 33   |
|                 | 100%        | 175% of control | DAGK    | MCF-7 cells          | 34   |
|                 | 100%        | 250% of control | DAGK    | L929                 | 35   |
|                 | 5 pmol/nmol LP | 13 pmol/nmol LP | DAGK    | U937 cells           | 36   |
|                 | 5 pmol/nmol LP | 12 pmol/nmol LP | DAGK    | SK2                  | 36   |
| Serum starvation| 100%        | 200% of control | DAGK    | Mouse keratinocytes  | 37   |
| LPS             | 2.8 pmol/nmol LP | 4.3 pmol/nmol LP | HPLC    | Brain                | 38   |
|                 | 4 nmol/ml    | 8 nmol/ml       | HPLC    | Plasma               | 38   |
|                 | 3.2 nmol/ml  | 4.8 nmol/ml     | HPLC    | Mouse serum,         | 39   |
|                 | 100%        | 200-500% of contr. | HPLC    | Human plasma         | 39   |
|                 | 3.5 nM/mg Pr | 16 nM/mg Pr     | HPLC    | THP-1 cells          | 40   |
|                 | 258 pmol/mg Pr | 1634 pmol/mg Pr | HPLC    | Mouse Mø             | 41   |
|                 | 8 nM/mg Pr   | 22 nM/mg Pr     | HPLC    | Human alveolar Mø     | 42   |
|                 | 1.1 nmol/mg Pr | 2.1 nmol/mg Pr  | DAGK    | Intestinal mucosa    | 43   |

*continued on next page*
Table 1. Continued

| Control                  | Treatment          | Assay    | Tissue/Cell Type | Ref. |
|--------------------------|--------------------|----------|------------------|------|
| ER stress                | 5 pmol/mg Pr       | Mass Spec| INS-1 cells      | 44   |
| Ionizing radiation       | 100%               | 700% of control | DAGK | OLG | 45   |
| 0.95 nmol/10^6 cells     | 100%               | 320% of control | DAGK | BAEC | 46   |
| 6-12 nmol/ml             | 100%               | 25% of control | DAGK | Keratinocytes | 47   |
| 10 pmol/10^6 cells       | 100%               | 130% of control | Mass Spec | Jurkat cells | 50   |
| 10 pmol/nmol LP          | 100%               | 140% of control | Mass Spec | Jurkat T-cells | 51   |
| Diabetes/obesity         | 0.5 pmol/µg Pr     | 1.0 pmol/µg Pr | DAGK | Rat heart tissue | 52   |
| 12 pmol/mg tissue        | 25 pmol/mg tissue | 23 pmol/mg | Mass Spec | Muscle | 56   |
| 0.2 nmol/mg tissue       | 15 pmol/mg         | 23 pmol/mg | Mass Spec | Muscle | 57   |
| 100%                     | 3.5 pmol/µl        | 9 pmol/µl | Mass Spec | Liver | 57   |
| 5 nmol/ml                | 0.5 nmol/mg Pr     | 1.5 nmol/mg Pr | Mass Spec | Human plasma | 58   |
| 2.4 nmol/ml              | 3.1 nmol/ml        | 2.4 nmol/ml | Mass Spec | Epididymal fat | 59   |
| 120 pmol/150µl           | 310 pmol/150µl     | 210 pmol/150µl | Mass Spec | Epididymal fat | 60   |
| 380 pmol/mg Pr           | 5 nmol/g           | 8 nmol/g | Mass Spec | Subcutaneous fat | 61   |
| 300 pmol/mg Pr           | 0.6 nmol/mg Pr     | 1.2 nmol/mg Pr | DAGK | Pancreatic islets | 62   |
| 650 pmol/ml              | 250 pmol/mg Pr     | 180 pmol/mg Pr | Mass Spec | Retina | 63   |
| Aging                    | 100%               | 100%     | Mass Spec | Cerebral cortex | 64   |
| 175 pmol/µg DNA          | 175% of control    | DAGK     | Heart | 66   |
| 0.45% of total LP        | Mass Spec | Adipose tissue | 67   |
| 1.3 nmol/mg Pr           | 1.7 nmol/mg Pr     | HPLC     | Liver | 68   |
| 0.5 pmol/mg Pr           | 1.1 pmol/mg Pr     | HPLC     | Rat hepatocytes | 69   |
| 3.5 pmol/nmol LP         | 1.5 pmol/mg Pr     | DAGK     | Endothelium | 70   |
| Alzheimer's disease      | 27 nM/ml           | 52 nM/ml | DAGK | CSF | 71   |
| 100%                     | 25% of control     | Mass Spec | Brain | 72   |
| 2.5 nmol/mg Pr           | Mass Spec | Temporal cortex | 73   |
| 2.0 nmol/mg Pr           | Mass Spec | Cerebellum | 74   |
| Heat stress              | 1.5 pmol/nmol LP   | 3.8 pmol/nmol LP | DAGK | Molt-4 | 75   |

continued on next page
### Table 1. Continued

| Control                      | Treatment | Assay   | Tissue/Cell Type       | Ref. |
|------------------------------|-----------|---------|------------------------|------|
| Oxidative stress             | 100%      | 800% of control | DAGK | Human primary | 77  |
|                               | 100%      | 200% of control | DAGK | OLG | 78  |
|                               | 100%      | 170% of control | DAGK | Cerebral cortex | 79  |
|                               | 100%      | 200% of control | DAGK | PC12 | 80  |
|                               | 100%      | 350% of control | Mass Spec | Airway epithelium | 81  |
|                               | 100%      | 140% of control | Labeling | APRE-19 | 82  |
|                               | 100%      | 180% of control | DAGK | SMC | 83  |
|                               | 90%       | 100% of control | DAGK | HAEC |      |
|                               | 90%       | 20% of control | DAGK | CHLA |      |
|                               | 90%       | 60% of control | DAGK | U937 |      |
|                               | 90%       | 80% of control | DAGK | MCF-7 |      |
|                               | 90%       | 90% of control | DAGK | Hs-578T |      |
|                               | 90%       | 20% of control | DAGK | T47D |      |
|                               | 90%       | 80% of control | DAGK | MCF-7 |      |
|                               | 90%       | 80% of control | DAGK | CHLA-90 |      |
| 7 pmol/nmol LP                | 100%      | 1000% of control | Labeling | LnCaP | 87  |
|                               | 100%      | 200% of control | Labeling | PC-3 | 87  |
|                               | 100%      | 70 pmol/nmol LP | DAGK | MDA-MB 231 | 88  |
|                               | 100%      | 70 pmol/nmol LP | DAGK | MDA-MB 468 | 89  |
|                               | 100%      | 220% of control | Labeling | MDA-MB 231 | 92  |
|                               | 100%      | 350% of control | Labeling | MDA-MB 468 | 92  |
|                               | 100%      | 10% of total LP | Labeling | MCF-7 | 90  |
|                               | 100%      | 90% of control | Labeling | MCF-7 | 91  |
|                               | 100%      | 180% of control | Labeling | BT-20 | 92  |
|                               | 100%      | 300% of control | Labeling | MCF-7 | 92  |
|                               | 100%      | 650% of control | Labeling | MDA-MB 231 | 92  |
|                               | 100%      | 650% of control | Labeling | MDA-MB 468 | 92  |
|                               | 100%      | 300% of control | Labeling | Hs-578T | 92  |
|                               | 100%      | 380% of control | Labeling | T47D | 92  |
|                               | 100%      | 620% of control | Labeling | MCF-7 | 92  |
|                               | 100%      | 700% of control | Labeling | HL-60/VCR | 93  |
|                               | 100%      | 220% of control | Labeling | U-937 | 93  |
|                               | 100%      | 220% of control | Labeling | CHLA-90 | 94  |
|                               | 0.6 ng/10^6 cells | 1.8 ng/10^6 cells | DAGK | JHU-022 | 95  |

In some cases numerical values were taken from graphically represented data and were rounded to the nearest whole number. Abbreviations: General: CSF, cerebrospinal fluid; DAGK, diacylglycerol Kinase; LP, lipid phosphate; Mø, primary macrophages; OLG, oligodendrocytes; Pr, Protein. Cells lines: A775, rat embryonic thoracic aorta smooth muscle; APRE-19, human retinal pigment epithelium; BAEC, bovine aortic endothelium; BT-20—human breast carcinoma; CG4, oligodendrocyte progenitor; CHK, Chinese hamster kidney; CHLA-90, human neuroblastoma; HAE, human airway epithelial; HDF, human diploid fibroblasts; HEK 293, human embryonic kidney; HeLa, cervical carcinoma; HL60/VCR, drug resistant human leukemia; Hs-578T, breast carcinoma; HUVEC, human umbilical vein endothelium; INS-1, rat insulinoma; JHU-022, squamous cell carcinoma; Jurkat, T-lymphocytes; L929, mouse fibroblasts; MDA-MB 231, human Caucasian breast adenocarcinoma; MDA-MB 468, human Black breast adenocarcinoma; MCF-7, human breast adenocarcinoma; MIN6, murine beta cells; Molt-4, human acute lymphoblastic leukemia; LnCaP, human prostate carcinoma; NRK-52E, rat kidney epithelium; NT-2, human neuronal precursor; PC3, human prostate carcinoma; PC12, rat adrenal medulla carcinoma; SK2, hybridoma; SP-1, mammary intraductal adenocarcinoma; T47D, human ductal breast epithelial tumor; TNP-1, human acute monocytic leukemia; U87, human astrocytoma; U937, human leukemic monocyte lymphoma.
suggest that ceramide plays the role of a gauge that senses the level of cell injury and depending on downstream factors determines specific biological outcome.3

**Mechanisms for Ceramide Generation during Stress**

Ceramide does not move spontaneously between cellular membranes and is transported either during normal membrane biogenesis, or with the aid of CERT, a protein that transfers ceramides synthesized at the endoplasmic reticulum to the Golgi apparatus. This insolubility of ceramide suggests that once generated, ceramide is likely to remain localized at the place of its synthesis until metabolized to other sphingolipids. Consequently, the increases in ceramide concentration during stress response are compartmentalized in distinct locations within the cells and might affect diverse sets of downstream targets and responses.

The two main metabolic pathways for generation of excess ceramide during stress response are (i) the de novo synthesis in the endoplasmic reticulum and (ii) the turnover of sphingomyelin (SM) either at the plasma membrane or in the endosomal/lysosomal compartment (Fig. 2). A number of agonists have been shown to activate these pathways leading to transient elevation in ceramide. The magnitude and temporal pattern of ceramide accumulation is further influenced by the activity of ceramidases, SM synthases, ceramide kinase and glucosyl/galactosyl ceramide synthases. These enzymes catalyze the conversion of ceramide to other sphingolipids and some agonists seem to coordinately regulate both, the ceramide production and turnover.20,96

**Role of the De Novo Pathway for Ceramide Generation in Cellular Stress Response**

The de novo pathway for synthesis of ceramide consists of 4 reactions: the serine palmitoyltransferase (SPT), which condenses palmitoyl-CoA and serine into 3-ketosphinganine, the 3-ketosphinganine reductase that generates sphinganine, the (dihydro)ceramide synthase, which

---

**Figure 2.** Metabolic pathways responsible for ceramide synthesis and degradation. The pools of ceramide involved in cellular response to stress are depicted in capital letters. Name of the enzymes are in *plain italic*. The names of relevant subcellular organelles are shown in *bold italic*. Black solid arrows are used to depict metabolic conversions. Black dashed arrow indicates protein-mediated transfer. White dashed arrow indicates vesicular transport. Abbreviations: SPT: Serine Palmitoyltransferase; Cers: Ceramide synthases; CerT: ceramide transfer protein. SMS1 & 2: sphingomyelin synthase 1 & 2; smpd1: Acid Sphingomyelinase, smpd2: Neutral sphingomyelinase1, smpd3: Neutral sphingomyelinase 2. CerK1, Ceramide Kinase; SK: sphingosine Kinase. ACeramidase: Acid Ceramidase.
acylates sphinganine to dihydroceramide and the dihydroceramide desaturase, which converts relatively inactive dihydroceramides to ceramides. Stimulation of the de novo pathway during cellular stress response happens through up-regulation of the activity of SPT and/or (dihydro) ceramide synthase. The newly generated ceramide is actively transported to the Golgi apparatus, where it serves as a rate-limiting substrate in the synthesis of complex sphingolipids, like SM and glycosphingolipids. It is noteworthy that some of the known ceramidases may also act as ceramide synthases in a CoA-dependent and independent manner as they exhibit reverse activity. This alternative route for ceramide synthesis is often referred to as the salvage pathway and its role in stress response is not well understood.

The activation of the de novo pathway apparently leads not only to an elevation in ceramide but also to increases in the concentration of SM and glycosphingolipids. Such parallel accumulation is documented in response to LPS, palmitate treatment and heat shock, among others and implies that a wide range of cell functions might be affected through specific and nonspecific mechanisms. Inhibitors of glucosylceramide synthase and labeling with radioactive precursors have been successfully used to elucidate the specific role of ceramide in each case.

\textit{De novo} synthesis of ceramide is target of a number of fungal inhibitors like fumonisin B1, which inhibits dihydroceramide synthase and the reverse reaction of some ceramidases\textsuperscript{97} and myriocin/ISP-1,\textsuperscript{98} cycloserine\textsuperscript{99} and beta-chloroalanine,\textsuperscript{100} all of which inhibit SPT. These widely used inhibitors retain a critical test of establishing whether the de novo pathway is involved in a particular cellular response (reviewed in Merrill\textsuperscript{101} and in Perry\textsuperscript{96}).

The activation of the de novo pathway during conditions of stress was initially discovered in yeast, where it regulates growth and the response to heat or osmotic stress (reviewed in Dickson\textsuperscript{102} and in Meier et al\textsuperscript{103}). However, in yeast the signaling mediator is not ceramide but the free long chain bases, phytosphingosine and dihydrophosphinosine, most likely reflecting the specifics of sphingolipid synthesis in yeast. Later, the activation of the de novo pathway in C. Elegans in response to ionizing radiation was described and found to be involved in activation of the CED-3 caspase\textsuperscript{104} and the resulting apoptosis of germ cells.

In mammalian systems, the de novo pathway seems to play a prominent role in cellular response to heat or chemical stress,\textsuperscript{105} septic shock,\textsuperscript{106} lipo-apoptosis\textsuperscript{107} and insulin resistance,\textsuperscript{108} as well as in receptor-dependent and -independent induction of apoptosis by variety of chemotherapeutic agents like etoposides\textsuperscript{109} and doxorubicin.\textsuperscript{110}

\textbf{Heat Stress}

In the human acute lymphoblastic leukemia cell line Molt-4, heat shock induces more than twofold increase in total ceramide levels with C16 ceramide being the major species affected. This accumulation of ceramide has been linked to the induction of c-jun and apoptosis.\textsuperscript{105} Labeling with tritiated palmitate has shown an accumulation of ceramides, but not sphingoid bases, thus confirming that in contrast to yeast, where sphingoid bases mediate heat shock, in mammals, ceramide is apparently involved. Both, myriocin and fumonisin B1 inhibit the increase in total ceramide mass thus confirming that ceramides produced upon heat shock were products of SPT and ceramide synthase activity.

\textbf{Septic Shock}

Similar observations delineate a role of the de novo synthesized ceramide in septic shock in vitro as well as in vivo.\textsuperscript{106} Administration of LPS or cytokines to rabbits increases hepatic sphingolipid biosynthesis leading to the accumulation of ceramide, SM and glycosphingolipids. Studies in cell lines link the stimulation of the de novo pathway to the activation of the MAP kinases and NF\kappa B and respectively to the innate immune response. In nonhepatic tissues the elevation in ceramide biosynthesis during septic shock is correlated with the elevated glycosphingolipid synthesis that seems to play a role in pathogen recognition.

Activation of ceramide synthesis in the liver has been linked to production and secretion of lipoproteins enriched in ceramides, sphingomyelins and glycosphingolipids. The functions of
these lipoproteins with “altered” sphingolipid content was not well understood; it became clear however that the activation of the de novo synthesis during septic shock is paralleled by activation of another ceramide-generating enzyme, the Zn\textsuperscript{2+}-dependent secretory form of ASMase, termed SMase. This enzyme hydrolyses SM in the Low Density Lipoproteins (LDL), leading to a robust increase in LDL ceramide content. Several lines of evidence suggest that LDL that are rich in ceramide might mediate injury to the arterial wall during inflammation. LDL extracted from atherosclerotic plaques contain higher ceramide content as compared to LDL isolated from the plasma.\textsuperscript{111} Experimentally-induced elevation in LDL ceramide content has been further linked to higher rate of LDL aggregation\textsuperscript{112} and oxidation, as well as with an increased potential to induce apoptosis in microvascular endothelial cell.\textsuperscript{113}

**Lipotoxicity and Insulin Desensitization**

Consumption of diet rich in saturated fats (also known as Western diet) is the main risk factor for the development of insulin resistance, hyperglycemia and atherosclerosis. Palmitic acid is the main component of the Western diet and is linked to excessive accumulation of lipids in lean tissues, mainly muscle and liver, lipotoxicity and insulin resistance. Because SPT has almost exclusive preference for the CoA-thiol ester of palmitate, numerous studies have investigated whether Western diet affects de novo synthesis of ceramide. These studies have shown that excess palmitate (delivered via the consumption of Western diet, i.e. infusion, or directly added to cells in culture) stimulates the flux through the de novo pathway resulting in accumulation of ceramide, SM and glycosphingolipids.\textsuperscript{38,114} Inhibition of SPT by myriocin prevents not only the palmitate flux through the pathway but also inhibits lipotoxicity, improves insulin response and leads to better glucose regulation.

The exact mechanism by which ceramide affects insulin response is not completely understood. Schmitz-Peiffer et al\textsuperscript{115} observed that the accumulation of ceramide in myotubes exposed to palmitate was paralleled by inhibition of Akt/PKB. Cotreatment with myriocin, cycloserine, or fumonisin B1 restored insulin-stimulated Akt phosphorylation, even in the presence of excess palmitate, suggesting that palmitate-induced stimulation of de novo synthesis is required for inhibition of insulin responsiveness. Recent data however imply that in vivo, the diet-induced ceramide increases have to be accompanied by increased triacylglycerides synthesis and accumulation in order to affect the overall insulin response. Furthermore, stimulation of the de novo synthesis of sphingolipids and that of triacylglycerides seems to be correlated in liver.\textsuperscript{59}

**Programmed Cell Death**

Perhaps, the most extensively studied cellular response to ceramide is the induction of programmed cell death or apoptosis. Activation of (dihydro)ceramide synthase in particular is implicated in endothelial cell death induced by TNF\textsubscript{alpha},\textsuperscript{116} in daunorubicin,\textsuperscript{10} doxorubicin and gemcitabine-induced apoptosis and may account for some aspects of the toxicity of phorbol esters,\textsuperscript{117} angiotensin II,\textsuperscript{118} cannabinoids\textsuperscript{119} and ischemia-reperfusion. In the latter case, investigation of intracellular sites of ceramide accumulation reveals that the elevation of ceramide is in mitochondria and is caused by the activation of a mitochondrial ceramide synthase via posttranslational mechanisms. Furthermore, ceramide accumulation appears to cause mitochondrial respiratory chain damage that could be mimicked by exogenously added natural ceramide to mitochondria.\textsuperscript{12}

The recent cloning and characterization of 6 members of the ceramide synthase family CerS1-6 (also known as longevity assurance gene 1-6 (LASS1-6)) provided the opportunity to finally begin studying the role of these enzymes in apoptosis in more details. CerS1 but not CerS2-6 for example, was found to be sufficient and required for apoptosis in response to gemcitabine/doxorubicin treatment.\textsuperscript{120} Notably, the gemcitabine/doxorubicin combination treatment was discovered to increase only the levels of C18-ceramide, the preferable substrate for CerS1. These and other studies have provided experimental evidence to the earlier assumptions that not only the type of sphingoid base (i.e., sphingosine vs sphinganine) but also the fatty acid length and degree of saturation influences the biological effectiveness of ceramide.
The role of the de novo pathway in apoptosis had also been investigated in different animal models. Inhibition of the enzymes controlling the de novo pathway prevents alveolar cell apoptosis, oxidative stress and emphysema (the prevalent disease caused by cigarette smoking) in both rats and mice, delays the progression of atherosclerotic plaques in mice and ameliorates some of the pathological consequences of spinal cord injury.

**Autophagy**

The final paradigm to be discussed is the role of the de novo synthesis of ceramide in autophagy, an evolutionary conserved cytoprotective mechanism that sustains cells during periods of nutrient limitation, but under certain conditions may lead to mammalian cell death. Ceramide addition is sufficient to induce autophagy in some cells and a correlation between the rate of autophagy and ceramide synthesis has been observed in same pathological conditions suggesting a mechanistic link between ceramide, autophagy and disease (reviewed in Zheng et al). Activation of de novo ceramide synthesis mediates autophagy in response to a bioenergetic crisis resulting in the rapid and profound down regulation of nutrient transporter proteins. Ceramide is also shown to mediate the tamoxifen-dependent accumulation of autophagic vacuoles in the human breast cancer MCF-7 cells and to counteract interleukin 13-dependent inhibition of macroautophagy in HT29 cells. The mechanism seems to involve the pro-autophagic protein beclin 1.

**Mechanisms of Activation of De Novo Synthesis of Ceramide during Stress**

Regulation of SPT at a transcriptional level has been seen with a number of agents, including endotoxin and cytokines, UVB irradiation and others. Induction of both form of SPT, SPT1 and SPT2, occurs in balloon-injured rat carotid artery. In contrast, long-term consumption of food rich in palmitate is correlated with increases in SPT1 protein but not mRNA level. Activation of SPT occurs also posttranslationally in response to etoposide and to heat shock in yeast. Mitochondrial injury in cerebral ischemia/reperfusion activates ceramide synthases via posttranslational mechanism which is dependent of JNK. Cers mRNA transcription is up-regulated in response to a gemcitabine/doxorubicin combination treatment, while cisplatin is shown to cause a specific translocation of Cers1 from the endoplasmic reticulum to the Golgi apparatus. The de novo pathway is also modulated through a negative feedback mechanism determined by the rate of sphingolipid degradation in the lysosomes since lipoproteins, sphingosine phosphate and ASMase activity seems to inhibit the flux through it. This might be a mechanism to prevent excessive synthesis of ceramide during normal healthy state of the cell.

**Role of the Sphingomyelinases in Cellular Stress Response**

The SMase family is a group of biochemically and genetically different enzymes all of which hydrolyze SM to ceramide and phosphorylcholine. SMase activities with neutral and acidic pH optima are found in most mammalian cells and an enzyme active in alkaline pH is localized in the intestinal wall. Currently, research is focused on 4 genes encoding different mammalian SMases: smpd1 encodes two forms of acidic SMase, one associated with the endosomal/lysosomal compartment (ASMase) and a second one found in the plasma and the conditioned medium of stimulated cells (SSMase). smpd2 and smpd3 encode the Neutral SMase 1 (nSMase1) and 2 (nSMase2), both of which are Mg2+-dependent but differ in their subcellular localization and role in signaling. Data from several labs have shown that in mammalian cells, nSMase1 is a housekeeping enzyme with no particular function in signaling. The recently cloned zebra fish nSMase1, however seems to mediate heat-induced apoptosis in zebra fish embryonic cells. In mammalian cells, nSMase2 is regulated by cytokines like IL-1β and TNFα and mediates some of the cytokine effects. The recently cloned smpd4, is suggested to encode a novel form of NSMase, nSMase3 that is found predominantly in skeletal muscle and heart.
Neutral Sphingomyelinase

Hepatic Acute Phase Response

The acute phase response of liver is an essential component of the systemic host response to bacterial infection and injury and requires IL-1β, a prototypic inflammatory cytokine. Activation of NSMase by IL-1β resulting in transient elevation in ceramide concentration is observed in number of cells including hepatocytes, mesangial cells, EL-4 cells and it has been related to activation of TAK-1, JNK and NF-κB, all of which have important roles in the IL-1β cascade.135-137

In hepatocytes, specific silencing of nSMase2 with siRNA has only a minimal effect on the basal cellular NSMase activity, however it results in a complete inhibition of the IL-1β-stimulated NSMase activity.138 Therefore, nSMase2 is probably an inducible enzyme that contributes little to the basal turnover of SM, but at the same time it is also the only neutral SMase activated by IL-1β. The role of NSMase2 in the IL-1β signaling cascade is rather complex: seemingly, the activation of nSMase2 modulates the pattern of phosphorylation of JNK by IL-1β and respectively the magnitude of transcriptional induction of the hepatic acute phase proteins like C-Reactive Protein, α1 Acid Glycoprotein and Insulin-like Growth Factor Binding Protein-1. nSMase2 activation in hepatocytes leads to potentiation of JNK phosphorylation due to stabilization of the IL-1β receptor-associated kinase-1. The latter most likely involves a phosphatase, like the ceramide-activated protein phosphatase 2A (PP2A).139

Vascular Inflammation

Activation of nSMase2 by another pro-inflammatory cytokine, TNFα is well documented in various vasculature and various cancer cells.132,140,141 TNFα-induced nSMase2 activation is a prerequisite for endothelial nitric oxide synthase activation in HUVEC cells,135 as well as for the up-regulation in A549 lung epithelial cells of vascular cell adhesion molecule and intracellular adhesion molecule 1,141 all of which have prominent roles in vascular inflammatory responses.

Apoptosis

Studies into the activation of NSMase during apoptosis have focused mainly on the role of NSMase-mediated ceramide production in the apoptosis induced by 55 kDa receptor for TNFα.142 A protein factor associated with NSMase activation, FAN, which interacts with the membrane-proximal domain of the p55 receptor and couples stimulation of the receptor to neutral SMase activation, is required for TNFα-induced ceramide generation, caspase processing and apoptosis.143 Subsequent work in MCF-7 cells found that activation of NSMase in TNFα-stimulated cell death is upstream of mitochondrial changes, cytochrome C release and caspase-9 activation.144

Oxidative stress-induced cell death may also be attributed to activation of NSMase. Free oxygen (H₂O₂), but not nitrogen (ONOO⁻) radicals specifically activate nSMase2, while silencing nSMase2 prevents H₂O₂-induced apoptosis, but had no effect on ONOO⁻-induced apoptosis.85

Very recent studies had began to suggest that a novel form of neutral SMase, nSMase3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies and modulate the sensitivity of cancer cells to adriamycin-induced cell killing.145 Early studies seem to suggest that at least the overexpressed nSMase3 can be activated by TNFα within seconds of stimulation.

Growth Arrest

A number of studies have established a role for NSMase-generated ceramide in regulating the cell cycle and mediating growth arrest, possibly through dephosphorylation of retinoblastoma protein and/or regulation of cyclin dependent kinases. Serum withdrawal causes activation of NSMase and cell cycle arrest at G0/G1 in Molt-4 cells.146 Interestingly, a study focusing on genes up-regulated during confluence-induced arrest had initially identified nSMase2 as a confluence-arrest gene, CCA1, in rat 3Y1 cells.147 In line with that, nSMase2 seems to mediate confluence-induced growth arrest of MCF-7 cells. The latter was preceded by confluence-induced translocation of nSMase2 to the plasma membrane.148
Aging and Cancer

Constitutive up-regulation of nSMase2 and elevation of ceramide concentration during aging has been observed in liver, brain, macrophages and other tissues.\textsuperscript{149} This aging-associated elevation in ceramide seems important for the onset of aging process since it has been causally linked to hyperresponsiveness to IL-1β\textsuperscript{70} and LPS\textsuperscript{41} and to deregulation of nitric oxide production in endothelium.\textsuperscript{71} A substantial decline in hepatic GSH content, which is characteristic for the aging process, is responsible for this constitutive increase in nSMase2 activity.\textsuperscript{150} nSMase2 apparently follows a pattern of regulation consistent with “developmental-aging” continuum, since in animal models of delayed aging, like calorie-restricted animals, the aging-associated changes in NSMase activity and function are reversed.\textsuperscript{150} In cellular model of senescence, similar induction of NSMase activity and accumulation of ceramide has been observed in senescent cells and linked to the decline in proliferative capacity and onset of senescence.\textsuperscript{72}

In contrast, a somatic homozygous deletion specifically targeting nSMase2 (Smpd3) is found in a genomic screen for gene copy losses contributing to tumorigenesis in a mouse osteosarcoma model, while loss-of-function mutations in smpd3 gene were identified in 5% of acute myeloid leukemia and 6% of acute lymphoid leukemia cancers. It has been suggested that the mutation could be linked to a defect in plasma membrane translocation of nSMase2 and decreased responsiveness to TNFα. Reconstitution of smpd3 expression in mouse tumor cells lacking the endogenous gene enhances the TNFα-induced reduction of cell viability.\textsuperscript{131}

Mechanisms of Activation of NSMase

(i) Translocation: Studies have shown that nSMase2 can be translocated to the plasma membrane when cell confluence is reached.\textsuperscript{152} This translocation of nSMase2 is also required for the confluence-induced cell cycle arrest to ensue.\textsuperscript{152} In oligodendroma-derived cells, a regulated translocation of NSMase2 to the caveolae, which are the signaling domains of the plasma membrane\textsuperscript{153} has been observed, while studies with highly differentiated nonproliferating primary hepatocytes have shown that the overexpressed nSMase2 is localized constitutively at the plasma membrane.\textsuperscript{133} These data suggest that translocation of nSMase2 to the plasma membrane might be important mechanisms for regulation of its activity \textit{in situ} by bringing the enzyme into contact with its substrates. Pharmacological inhibitors and specific siRNA has implicated the novel PKC, specifically PKCδ, in TNF and PMA-stimulated nSMase2 translocation to the plasma membrane.\textsuperscript{52}

(ii) NSMase as a redox-sensitive enzyme. The major scavenger of reactive oxygen species, GSH, has been found to be a reversible inhibitor of cellular NSMase activity.\textsuperscript{33,154} This is noteworthy, because depletion of cellular GSH content is observed in conditions of increased oxidative stress. The modulation of NSMase activity by GSH was first established in the context of regulation of TNFα signaling and apoptosis.\textsuperscript{33,154} Later, the ability of GSH to affect the sensitivity of T47D/H3 breast cancer cells to doxorubicin was attributed to the inhibitory effect GSH has on NSMase activity.\textsuperscript{155} A correlation between oxidative stress and NSMase activity was also found in long-lived rats on vitamin Q10 enriched diet\textsuperscript{156} and in astrocytes treated with vitamin E.\textsuperscript{157} Finally, recent research has shown that specific downregulation of nSMase2 with siRNA blocks H$_2$O$_2$-induced apoptosis of human aortic endothelial cells, identifying nSMase2 as a redox-sensitive protein.\textsuperscript{158} Detailed analyses of sensitivity of nSMase2 to GSH in hepatocytes suggest that GSH depletion exerts its effect on NSMase activity following a sigmoid dose dependent curve. A rapid and significant activation of NSMase is observed only when hepatic GSH concentration drops below 30% of its basal level, implying that there is a threshold required for NSMase activation during oxidative stress.\textsuperscript{130} Interestingly, nSMase1 is also sensitive to changes in the GSH/GSSG ratio.\textsuperscript{159} This suggests that redox sensitivity might be a common property of neutral SMases.
Acid Sphingomyelinase

Endotoxic Shock
Patients with severe sepsis exhibit an enhanced SMase activity in plasma. The increase is correlated with the severity of illness and the fatal outcome. Studies in humans and mice administered with LPS confirm these observations. Deletion of ASMase protects against LPS-induced elevation in the plasma SMase activity and attenuates endothelial apoptosis and animal death implicating a secretory isoform of ASMase (SSMase) in apoptosis and organ failure in sepsis. The physiological and biochemical properties of this SSMase are not well understood. It has been postulated that SSMase degrades SM in the secreted cell outer membrane leaflet, which contains almost ¾ of the cellular SM. This SM pool is seemingly inaccessible for other cellular SMases, since the active center of nSMase2, the sole plasma membrane-associated SMase, is facing the cytosolic leaflet of the membrane. These proposed autocrine functions of SSMase however had not been rigorously tested. In turn, substantial evidence had implicated SSMase in modifying the SM/ceramide content of circulating LDL as discussed earlier in the chapter.

Apoptosis (reviewed in ref. 162)
Irradiation of tumor cells with ionizing radiation transiently activates ASMase with maximal activity detected between 1 to 10 min post irradiation. The activation of ASMase has been linked to the ability of radiation to induce apoptosis since ASMase deficiency causes apoptosis resistance in various tissues in ex vivo or in vivo experiments. Genetic restoration of the activity also restores the radiation effects indicating that ASMase mediates apoptosis via ceramide, at least in some cells including B cells, endothelial cells or mesothelium, lung epithelial cells, MCF-7 breast cancer cells, etc. However, some other cell types, for example, thymocytes, remained sensitive to radiation in ASMase-deficient mice suggesting that radiation effects are mediated by different mechanisms depending on the cell type.

ASMase is also involved in death receptor-mediated apoptosis. Stimulation via the CD95 receptor leads to ASMase activation and ceramide accumulation that precedes the induction of cell death. Furthermore, studies with fibroblasts from Niemann–Pick disease type A patients, who exhibit deficiency of ASMase and hepatocytes from ASMase null mice show that ASMase activation is required and sufficient for CD95 induced apoptosis.

Viral and Bacterial Infections
Cellular ASMase activity seems to play an important role in susceptibility of mammalian organisms to microbial infections. ASMase-deficient mice were found to be more sensitive to infections with the Gram-negative bacteria L. monocytogenes, due to a defect in lyso-phagosomal fusion. In wild-type macrophages, the phagosome rapidly fuse with the lysosomes to form a phago-lyssosome and to kill and digest bacteria, while in macrophages deficient in ASMase the process is slower and leads to inefficient transfer of lysosomal antibacterial hydrolyses into phagosomes. Apparently, ASMase is required for the proper fusion of late phagosomes with lysosomes. ASMase-deficient mice were also more susceptible to infection with Sindbis virus, an enveloped virus with a single-stranded RNA that is involved in fatal alpha virus encephalomyelitis, due to more rapid replication and spread of the virus in the nervous system.

Mechanisms of Activation of ASMase
One mechanism for activation of ASMase involves its phosphorylation by PKCδ at Ser508 which mediates UV light-induced ASMase activation and cell death in MCF-7 breast cancer cells. Phosphorylation of ASMase seems to be correlated with its translocation to the plasma membrane (see below) in irradiated cells.

Evidence for a Coordinated Regulation of Multiple Pathways for Ceramide Generation
A handful of studies suggest that the activity of the two SMases and the de novo pathway might be regulated in a coordinated fashion by the same agonist, resulting in the transient
generation of distinct “waves” of ceramide increases that might serve to diversify the biological effects of ceramide. These studies also emphasize the significance of specific ceramide species in defined stages of cellular stress response.

For example, a transient increase of ceramide is observed within minutes after exposure to ionizing irradiation which is a consequence of DNA damage-independent acid SMase or neutral SMase activation.56 Several hours after irradiation, a second wave of ceramide accumulation is observed depending on the DNA damage-dependent activation of ceramide synthase. It seems that the late ceramide accumulation is also dependent on the first one and is rate limiting for the apoptotic process induced by irradiation.173

Kroesen et al174 on the other hand, showed that cross linking of the B-cell receptor generates C16-ceramide upstream of the mitochondria in a caspase independent manner and that inhibition of C16 ceramide generation rescues from cell death.56 C24 ceramide however was generated downstream of mitochondrial dysfunction in a caspase dependent manner. All of the increases are seemingly due to activation of de novo synthesis and apparently different members of the ceramide synthase family might be differentially regulated.

A classical example of coordinated regulation of neutral and acidic SMase is the early work of Kronke and colleagues.175 In these studies, stimulation with TNFα lead to activation of both enzymes through apparently separate mechanisms since different domains of the cytosolic tail of the TNFα receptor were responsible. Furthermore, while the activation of ASMase was linked to NFκB activation, NSMase seemed to regulate the activation of proline-directed serine/threonine protein kinase(s).

Mechanisms of Ceramide Effects on Cellular Functions

Ceramide-Interacting Molecules

PKCζ (reviewed in ref. 114)

PKCζ, atypical PKC isoform, was identified as a molecule that ceramide directly binds and activate. Notably, ceramide-induced activation of PKCζ is linked to inhibition of Akt-1. Akt-1 is a key regulatory molecule for various metabolic cellular functions, cell proliferation and cell death, which has been known for a long time to be inhibited by ceramide. Ceramide-activated PKCζ seems to phosphorylate Ser34 of the Akt-1 pleckstrin homology domain, thus preventing the interaction of Akt-1 with PIP3 and respectively with the plasma membrane.176-178 In addition to stimulating the kinase activity of PKCζ, ceramide binding seems to affect the ability of PKCζ to interact with other proteins. In vascular smooth muscle, ceramide stabilizes the interaction of Akt-1 and PKCζ within caveolin-enriched lipid microdomains to inactivate Akt and specifically reduces the association of PKCζ with 14-3-3, a scaffold protein localized to less structured regions within membranes.179 In differentiating embryonic stem cells, ceramide binding to PKCζ similarly leads to activation of its kinase activity but also increases PKCζ binding to its inhibitor protein, prostate apoptosis response-4 (PAR-4), thus compromising the antiapoptotic activity of PKCζ and inducing apoptosis.180

PP2A (reviewed in ref. 181)

Long chain D-erythro-C18-ceramide has been shown to activate PP2A (more specifically the ABC trimer), PP2AC and PP1-γC and -αC in vitro suggesting a direct and stereospecific effect of ceramide on the phosphatase activity. This ability of ceramide to activate PP2A was later found to mediate the ceramide effects on various substrates relevant to the induction of apoptosis, growth arrest or inflammation, including c-Jun, Bcl-2, Akt/PKB, Rb, PKCα, ERK1/2, IRAK-1, SR proteins and many others.

Cathepsin D

Ceramide specifically binds and activates the endosomal acidic aspartate protease cathepsin D. Direct interaction of ceramide with cathepsin D results in autocatalytic proteolysis of the 52 kDa procathepsin D to the enzymatically active 48/32 kDa isoforms that can subsequently
Ceramide in Stress Response

Cleave and activate the apoptotic regulator Bid. Studies in ASMase deficient cells strongly suggest that ASMase activity is responsible for the generation of ceramide that can activate the protease. This is in contrast to the ability of ceramide to activate PKCζ and PP2A, which seemingly requires activation of the de novo pathway or NSMase.

**Indirect Targets of Ceramide**

**Modulators of Apoptosis (reviewed in ref. 184)**

The members of the Bcl-2 family of proteins are essential modulators of apoptotic cell death following genotoxic and nongenotoxic stress. Strong evidence links ceramide to the regulation of two members of that family, the antiapoptotic Bcl-2 and the pro-apoptotic Bax. The mechanisms involved are far from understood and apparently quite complex. TNFα- and etoposide-induced activation of ASMase leads to apoptosis via a pathway where ceramide is upstream of the antiapoptotic member of the family, Bcl-2 and lead to its inhibition (5). These effects seem to involve PP2A. Bcl-2, whose phosphorylation at Ser70 is required for its anti-apoptotic function, becomes dephosphorylated in response to ceramide in a PP2A-dependent manner and consequently is degraded in the proteasomes. In turn, gemcitabine-induced ceramide generation is found to enhance the expression of proapoptotic Bcl-xL. Ceramide accumulation is also linked to the activation of the execution caspases, but it is downstream of the initiator caspases.

C16-ceramide, which is generated by ASMase in response to irradiation is shown to induce a conformation change of the pro-apoptotic member Bax leading to its activation and cytochrome C release. It was suggested that only the production of ceramide in the mitochondria can induce the oligomerization of Bax that drives cell death. As Bcl-2, Bax is also regulated by ceramide via PP2A, since its dephosphorylation is associated with conformational change and release of cytochrome C from the mitochondria. Ceramide generation by ASMase has been suggested to mediate cell death by caspase- dependent and independent mechanisms depending on the death stimulus.

**Regulators of Cell Cycle**

Dephosphorylation of the Retinoblastoma protein, activation of the cyclin dependent kinase inhibitor p21 and inhibition of the cyclin dependent kinase 2 are essential steps in the pathway leading to cell cycle arrest in response to ceramide accumulation. Ceramide induced-dephosphorylation of Retinoblastoma protein is mediated through PP2A, for which Retinoblastoma protein is a direct substrate. The hypophosphorylated Retinoblastoma protein binds and sequesters E2F, an essential factor for progression through the cell cycle. The senescent-associated growth may be attributed to a defect in the phospholipase D/protein kinase C (PLD/PKC) pathway and ceramide can inhibit both PLD and PKC.

**Regulators of Inflammation**

Studies by Hannun and Brenner were the first to show that TNFα activates the stress-activated protein kinases JNKs, resulting in the stimulation of AP-1-transcription factor and induces the translocation of NFκB to the nucleus, resulting in the stimulation of NFκB-dependent gene transcription, through ceramide. Ceramide induced JNK activation has also been reported in response to FAS activation, and many cytokines. The activation of JNK by ceramide involves Rac-1 in the case of radiation-induced apoptosis, PKCζ in response to IL-1β and TAK-1 in response to TNF-α, IL-1β, or anti-Fas antibody. In hepatocytes, nSMase2-generated ceramide has been shown to modulate the effects of IL-1β on JNK phosphorylation and activity in PP2A and IRAK-1-dependent manner.

Ceramide-mediated JNK activation inhibits differentiation of skeletal muscle progenitor cells to myoblasts and induces the expression of various acute phase proteins like Insulin-like Growth Factor Binding Protein-1 in liver. JNK activation mediates apoptosis in neurons in response to ceramide and Amyloid β, the protein involved in the etiology of Alzheimer’s disease. In that system, an inhibition of NSMase was found to attenuate Amyloid β-induced JNK phosphorylation and AP-1 DNA binding activity suggesting the involvement of the plasma membrane-associated SMase activity.
Sphingolipids as Signaling and Regulatory Molecules

Ceramide Effects on Membrane Organization

Some of the biological responses to ceramide generation are probably due to the effects ceramide has on the structure of membrane rafts and caveolae, on the membrane curvature and the membrane permeability to aqueous solutes. The two hydroxyl groups, the amid group protons and the trans-double bond in ceramide molecule, together with the lack of large hydrophilic head group determine the ability of ceramide to affect the properties and organization of biological membrane. The long-chain base and long saturated N-acyl chains accompanied by a very small hydrophilic head promote the partitioning of ceramide into ordered membrane domains. Together with SM, which has a strong affinity for interacting with membrane cholesterol, ceramide participate in the formation of the caveolae, the signaling platforms on the cell surface. While SM is by far much more abundant than ceramide in the lipid rafts, the generation of ceramide within rafts dramatically alters the biophysical properties of these membrane domains. Ceramide molecules have the tendency to spontaneously self associate to small ceramide-enriched membrane microdomains. Gullbins and colleagues had proposed that these ceramide microdomains spontaneously fuse to form large ceramide-enriched macrodomains or platforms. The formation of such platforms is proposed to underlie the process of agonist induced receptor clustering and consequently, the reorganization of intracellular signaling molecules to transmit a signal into the cell. Among the receptors affected by ceramide-mediated aggregation/clustering are CD95, CD28, TNFα, CD40, FcγRII. Intriguingly, the acidic form of SMase seems to be involved in the formation of these signaling platforms, since it has been shown to translocate to the plasma membrane under certain conditions. In further support to that extend, overexpression of the SM synthase, SMS-1, which enriches plasma membrane with SM also enhances the translocation of Fas into lipid rafts leading to subsequent Fas clustering, DISC formation, activation of caspases and apoptosis, suggesting that SM levels in the lipid rafts might also be a critical factor possible by acting as a source for ceramide.

Another intriguing property of ceramide is its ability to spontaneously form channels into planar bilayers, liposomes and biological membranes indicating that ceramide might regulate membrane leakiness. Experiments with unilamellar vesicles show that ceramide forms large pores that can allow the efflux of proteins as large as 60 kDa. Studies by Colombini and colleagues had shown that at physiologically relevant levels, ceramides form stable channels in mitochondrial outer membranes capable of passing the largest proteins known to exit mitochondria during apoptosis including cytochrome C. Ongoing efforts on characterizing the ceramide metabolism in this organelle will shed more light into the physiological function of ceramide in the mitochondria.

Finally, studies in cells isolated from ASMase-deficient mice or Niemann-Pick patients had shown defects in the phagolysosomal fusion and rab-4-mediated endocytosis indicating that ASMase regulates select vesicular fusion processes by modifying the steric conformation of cellular membranes. These conclusions are supported by series of studies on the infectivity of Listeria monocytogenes and Mycobacterium avium discussed earlier.

Conclusion

It was realized long ago that sphingolipid structure is highly diverse and encodes distinct chemical information that can be conveyed during cell signaling. Research spanning through the last two decades established experimentally the role of this novel family of bioactive lipids in signaling. Ceramide emerged as the key metabolite in several sphingolipid-based signaling networks and was recognized to mediate conserved pathways of cellular stress response. With the genetic cloning and characterization of the majority of ceramide metabolizing enzymes, it also became clear that ceramide metabolism is finely tuned leading to spatial, temporal and species-specific accumulation during stress. A strict substrate specificity and distinct cellular localization of the enzymes that catalyze ceramide synthesis and degradation has brought diversity in the signaling molecules and cellular responses regulated by ceramide. The distinct ability of ceramide to alter the biophysical properties of cellular membrane adds additional layer of complexity in our understanding of the roles of ceramide in cellular stress response.
References

1. GoOt FM, Alonso A. Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochimica et Biophysica Acta (BBA)—Biomembranes 2006; 1758:1902-1921.

2. Zheng W, Kollmeyer J, Symolon H et al. Ceramides and other bioactive sphingolipid backbones in health and disease: Lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochimica et Biophysica Acta (BBA)—Biomembranes 2006; 1758:1864-1884.

3. Ramstedt B, Slotte JP. Sphingolipids and the formation of sterol-enriched ordered membrane domains. Biochimica et Biophysica Acta (BBA)—Biomembranes 2006; 1758:1945-1956.

4. Shenar RL, Allegood JC, Park H et al. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res 2008.

5. Zhang J, Alter N, Reed JC et al. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc Natl Acad Sci USA 1996; 93:5325-5328.

6. Jin J, Hou Q, Mullen TD et al. Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells. J Biol Chem 2008; 283:26509-26517.

7. Hernandez OM, Discher DJ, Bishopric NH et al. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res 2000; 86:198-204.

8. Basnakian AG, Ueda N, Hong X et al. Ceramide synthase is essential for endonuclease-mediated death of renal tubular epithelial cells induced by hypoxia-reoxygenation. Am J Physiol Renal Physiol 2005; 288:F308-314.

9. Yoshimura S, Banno Y, Nakashima S et al. Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bel-2 on ceramide formation and caspase-3 activation. J Biol Chem 1998; 273:6921-6927.

10. Therade-Matharan S, Laemmle E, Carpentier S et al. Vicaut. Reactive oxygen species production by mitochondrial endothelial cells exposed to reoxygenation after hypoxia and glucose depletion is mediated by ceramide. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1756-1762.

11. Yan JK, Kester M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Arch Biochem Biophys 2002; 408:78-86.

12. Yu J, Novgorodov SA, Chudakov D et al. JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. J Biol Chem 2007; 282:25940-25949.

13. Bielawska AE, Shapiro JP, Jiang L et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by mitochondrial dysfunction. Am J Pathol 1997; 151:1257-1263.

14. Zager RA, Iwata M, Conrad DS et al. Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure. Kidney Int 1997; 52:60-70.

15. Llacuna L, Mari M, García-Ruiz C et al. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 2006; 44:561-572.

16. Singh I, Pahan K, Khan M et al. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem 1998; 273:20354-20362.

17. Brogi A, Strazza M, Melli M et al. Induction of intracellular ceramide by interleukin-1 beta in oligodendrocytes. J Cell Biochem 1997; 66:532-541.

18. Schreur KD, Liu S. Involvement of ceramide in inhibitory effect of IL-1 beta on L-type Ca2+ current in adult rat ventricular myocytes. Am J Physiol 1997; 272:H2591-2598.

19. Kaszkin M, Huwiler A, Scholz K et al. Negative regulation of interleukin-1beta-activated neutral sphingomyelinase by protein kinase C in rat mesangial cells. FEBS Lett 1998; 440:163-166.

20. Nikolova-Karakashian M, Morgan ET, Alexander C et al. Bimodal regulation of ceramide by interleukin-1beta. Implications for the regulation of cytochrome p450 2C11. J Biol Chem 1997; 272:18718-18724.

21. Chen J, Nikolova-Karakashian M, Merrill AH et al. Regulation of cytochrome P450 2C11 (CYP2C11) gene expression by interleukin-1, sphingomyelin hydrolysis and ceramides in rat hepatocytes. J Biol Chem 1995; 270:25233-25238.

22. Masamune A, Igarashi Y, Hakomori S. Regulatory role of ceramide in interleukin (IL)-1 beta-induced E-selectin expression in human umbilical vein endothelial cells. Ceramide enhances IL-1 beta action, but is not sufficient for E-selectin expression. J Biol Chem 1996; 271:9368-9375.

23. Sallusto F, Nicolò C, De Maria R et al. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med 1996; 184:2411-2416.

24. Schneider C, Delomez N, El Bebouri H et al. Martiny. Interleukin 1 beta (IL-1 beta) action in porcine thyroid cells involves the ceramide signalling pathway. Cytokine 2001; 13:174-178.

25. Liu J, Ginis I, Spatz M et al. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am J Physiol Cell Physiol 2000; 278: C144-153.
26. Sawada M, Kiyono T, Nakashima S et al. Molecular mechanisms of TNF-alpha-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ 2004; 11:997-1008.

27. Kitatani K, Akiba S, Sato T. Ceramide-induced enhancement of secretory phospholipase A2 expression via generation of reactive oxygen species in tumor necrosis factor-alpha-stimulated mesangial cells. Cell Sigmal 2004; 16:967-974.

28. Garcia-Ruiz C, Collell A, Mari M et al. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest 2003; 111:197-208.

29. Mallampalli RK, Peterson EJ, Carter AB et al. TNF-alpha increases ceramide without inducing apoptosis in alveolar type II epithelial cells. Am J Physiol 1999; 276: L491-490.

30. Ryan AJ, McCoy DM, McGowan SE et al. Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical activity. J Appl Physiol 2003; 94:253-258.

31. Medler TR, Petrusca DN, Lee PJ et al. Apoptotic sphingolipid signaling by ceramides in lung endothelial cells. Am J Respir Cell Mol Biol 2008; 38:639-646.

32. Ishizuka N, Yagui K, Tokuyama Y et al. Kanatsu. Tumor necrosis factor-alpha signaling pathway and apoptosis in pancreatic beta cells. Metabolism 1999; 48:1485-1492.

33. Liu B, Andrieu-Abadie N, Levade T et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 1998; 273:11313-11320.

34. Luberto C, Hassler DF, Signorelli P et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 2002; 277:11128-11139.

35. Strelow A, Bernardo K, Adams-Klages S et al. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 2000; 192:601-612.

36. Monney L, Olivier R, Otter I et al. Role of an acidic compartment in tumor-necrosis-factor-alpha-induced production of ceramide, activation of caspase-3 and apoptosis. Eur J Biochem 1998; 251:295-303.

37. Tsuji K, Mitsukata S, Yokose U et al. Role of ceramide kinase in peroxisome proliferator-activated receptor beta-induced cell survival of mouse keratinocytes. Febs J 2008; 275:3815-3826.

38. Zimmermann C, Ginis I, Furuya K et al. Mallenbeck. Lipopolysaccharide-induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. Brain Res 2001; 895:59-65.

39. Lightle S, Tosheva R, Lee A et al. Elevation of ceramide in serum lipoproteins during acute phase response in humans and mice: role of serum-palmitoyl transferase. Arch Biochem Biophys 2003; 419:120-128.

40. Cuscheri J, Billgren J, Maier RV. Phosphatidylcholine-specific phospholipase C (PC-PLC) is required for LPS-mediated macrophage activation through CD14. J Leukoc Biol 2006; 80:407-414.

41. Claycombe KJ, Wu D, Nikolova-Karakashian M et al. Ceramide mediates age-associated increase in macrophage cyclooxygenase-2 expression. J Biol Chem 2002; 277:30784-30791.

42. Monick MM, Mallampalli RK, Carter AB et al. Ceramide regulates lipopolysaccharide-induced phosphati-dylinositol 3-kinase and Akt activity in human alveolar macrophages. J Immunol 2001; 167:5977-5985.

43. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997; 186:1831-1841.

44. Lei X, Zhang S, Bohrer A et al. The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelin by neutral sphingomyelinase. Biochemistry 2007; 46:10170-10185.

45. Lu PG, Wong CS. Radiation-induced apoptosis of oligodendrocytes and its association with increased ceramide and down-regulated protein kinase B/Akt activity. Int J Radiat Biol 2004; 80:39-51.

46. Uchida Y, Nardo AD, Collins V et al. De novo ceramide synthesis participates in the ultraviolet B irradiation-induced apoptosis in undifferentiated cultured human keratinocytes. J Invest Dermatol 2003; 120:662-669.

47. Haimovitz-Friedman A, Kan CC, Ehleiter D et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994; 180:525-535.

48. Sathishkumar S, Boyanovsky B, Karakashian AA et al. Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis. Cancer Biol Ther 2005; 4:979-986.

49. Grether-Beck S, Bonizzi G, Schmitt-Brenden H et al. Non-enzymatic triggering of the ceramide signalling cascade by solar UVA radiation. EMBO J 2000; 19:5793-5800.

50. Thomas RL Jr, Matsko CM, Lotze MT et al. Mass spectrometric identification of increased C16 ceramide levels during apoptosis. J Biol Chem 1999; 274:30580-30585.

51. Chatterjee M, Wu S. Cell line dependent involvement of ceramide in ultraviolet light-induced apoptosis. Mol Cell Biochem 2001; 219:21-27.

52. Zeidan YH, Wu BX, Jenkins RW et al. A novel role for protein kinase Cdelta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury. FASEB J 2008; 22:183-193.

53. Dai Q, Liu J, Chen J et al. Mitochondrial ceramide increases in UV-irradiated HeLa cells and is mainly derived from hydrolysis of sphingomyelin. Oncogene 2004; 23:3650-3658.
54. Charruyer A, Grazide S, Bezombes C et al. UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem 2005; 280:19186-19204.
55. Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97:1784-1789.
56. Adams JM 2nd, Pratipanawatr T, Berria R et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53:25-31.
57. Turinsky J, O’Sullivan DM, Bayly BP. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 1990; 265:16880-16885.
58. Holland WL, Brozniczki JT, Wang LP et al. Summers. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat- and obesity-induced insulin resistance. Cell Metab 2007; 5:167-179.
59. Deevska GM, Rozenvaeva KA, Giltiay NV et al. Acid sphingomyelinase deficiency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. J Biol Chem 2008.
60. Haus JM, Kashyap SR, Kasumov T et al. Plasma Ceramides Are Elevated in Obese Subjects with Type 2 Diabetes and Correlate with the Severity of Insulin Resistance. Diabetes 2008.
61. Shah C, Yang G, Lee I et al. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008; 283:13538-13548.
62. Samad F, Hester KD, Yang G et al. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006; 55:2579-2587.
63. Kolak M, Westerbacka J, Velagapudi VR et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56:1960-1968.
64. Shimabukuro M, Zhou YT, Levi M et al. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95:2498-2502.
65. Fox TE, Han X, Kelly S et al. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes 2006; 55:3573-3580.
66. Costantini C, Scoble H, Puglielli L. An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide regulation is associated with enhanced ceramide levels in age-associated cardiac hypertrophy. J Gerontol A Biol Sci Med Sci 2007; 62:1326-1336.
67. Wu D, Ren Z, Pae M et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol 2007; 179:4829-4839.
68. Lightle SA, Oakley JL, Nikolova-Karakashian MN. Activation of sphingolipid turnover and chronic generation of ceramide and sphingosine in liver during aging. Mech Ageing Dev 2000; 120:111-125.
69. Rutkute K, Karakashian AA, Giltiay NV et al. Aging in rat causes hepatic hyperglyceremia in the liver in vivo. Exp Neurol 2001; 169:425-437.
70. Rutzke R, Visioli F, Frei B et al. Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide-activated phosphatase 2A. Aging Cell 2006; 5:391-400.
71. Venable ME, Lee JY, Smyth MJ et al. Role of ceramide in cellular senescence. J Biol Chem 1995; 270:30701-30708.
72. Sato H, Tomimoto H, Ohtani R et al. Astroglial expression of ceramide in Alzheimer’s disease brains: a role during neuronal apoptosis. Neuroscience 2005; 130:657-666.
73. Catter RG, Kelly J, Storie K et al. Involvement of oxidative-stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 2004; 101:2070-2075.
74. Han X, MH D, McKee DW Jr et al. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J Neurochem 2002; 82:809-818.
75. Jenkins GM, Cowart LA, Signorelli P et al. Acute activation of de novo sphingolipid biosynthesis upon heat shock causes an accumulation of ceramide and subsequent dephosphorylation of SR proteins. J Biol Chem 2002; 277:42572-42578.
76. Jana A, Pahan K. Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmun Pharmacol 2007; 2:184-193.
77. Song JH, Shin SH, Ross GM. Oxidative stress induced by ascorbate causes neuronal damage in an in vitro system. Brain Res 2001; 895:66-72.
78. Song JH, Shin SH, Wang W et al. Involvement of oxidative stress in ascorbate-induced proapoptotic death of PC12 cells. Exp Neurol 2001; 169:425-437.
79. Goldkorn T, Balaban N, Shannon M et al. H2O2 acts on cellular membranes to generate ceramide signaling and initiate apoptosis in tracheobronchial epithelial cells. J Cell Sci 1998; 111 (Pt 21):3209-3220.
80. Yamada V, Tian J, Yang Y et al. Oxidized low density lipoproteins induce a pathologic response by retinal pigmented epithelial cells. J Neurochem 2008; 105:1187-1197.
82. Auge N, Nikolova-Karakashian M, Carpenter S et al. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase and sphingosine kinase. J Biol Chem 1999; 274:21533-21538.

83. Castillo SS, Levy M, Thakooratthil JV et al. Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp Cell Res 2007; 313:2680-2686.

84. Park TS, Ha Y, Noh HL et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49:2101-2112.

85. Karpanen T, Bry M, Ollila HM et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008; 103:1018-1026.

86. Ichi H, Nakahara K, Miyashita Y et al. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 2006; 41:859-863.

87. Wang H, Charles AG, Frankel AJ et al. Increasing intracellular ceramide: an approach that enhances the cytotoxic effect in prostate cancer cells. Urology 2003; 61:1047-1052.

88. Scarlatti F, Sala G, Somenzi G et al. Revestratol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003; 17:2339-2341.

89. Charles AG, Han TY, Liu YY et al. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001; 47:444-450.

90. Roberts CG, Gurisik E, Biden TJ et al. Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism. Mol Cancer Ther 2007; 6:2777-2785.

91. Cabor MC, Han TY, Giuliano AE. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett 1998; 431:185-188.

92. Wang H, Giuliano AE, Cabot MC. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol Cancer Ther 2002; 1:719-726.

93. Senchenkov A, Han TY, Wang H et al. Enhanced ceramide generation and apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diptheria toxin fused to human GM-CSF. Blood 2001; 98:1927-1934.

94. Wang H, Maurer BJ, Reynolds CP et al. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001; 61:5102-5105.

95. Gu X, Song X, Dong Y et al. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2008; 14:1840-1848.

96. Coroneos E, Wang Y, Panuska JR et al. Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades. Biochem J 1996; 316 [Pt 1]:13-17.

97. Merrill AH Jr, van Echten G, Wang E et al. Fumonisin B1 inhibits sphingosine (sphinganine) N-acetyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 1993; 268:27299-27306.

98. Paumen MB, Ishida Y, Muramatsu M et al. Inhibition of Carnitine Palmitoyltransferase I Augments Sphingolipid Synthesis and Palmitate-induced Apoptosis. J Biol Chem 1997; 272:3324-3329.

99. Blazquez C, Galvez-Rojo I, Guzman M. De novo-synthesized ceramide signals apoptosis in astrocytes via extracellular signal-regulated kinase. FASEB J 2000; 14:2315-2322.

100. Lehrenen JYA, Horuchi M, Davier L et al. Activation of the de novo Biosynthesis of Sphingolipids Mediates Angiogenesis II Type 2Receptor-induced Apoptosis. J Biol Chem 1999; 274:16901-16906.

101. Merrill AH Jr. De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, Pathway. J Biol Chem 2002; 277:25843-25846.

102. Dickson RC. Thematic Review Series: Sphingolipids. New insights into sphingolipid metabolism and function in budding yeast. J Lipid Res 2008; 49:909-921.

103. Meier KD, Deloche O, Kajiwara K et al. Sphingoid base is required for translation initiation during heat stress in Saccharomyces cerevisiae. Mol Biol Cell 2006; 17:1164-1175.

104. Deng X, Yin X, Allan R et al. Ceramide Biogenesis Is Required for Radiation-Induced Apoptosis in the Germ Line of C. elegans. Science 2008; 322:110-115.

105. Jenkins GM. The emerging role for sphingolipids in the eukaryotic heat shock response. Cell Mol Life Sci 2003; 60:701-710.

106. Memon RA, Holleran WM, Moser AH et al. Endotoxin and Cytokines Increase Hepatic Sphingolipid Biosynthesis and Produce Lipoproteins Enriched in Ceramides and Sphingomyelin. Arterioscler Thromb Vasc Biol 1998; 18:1257-1265.

107. Shimabukuro M, Higa M, Zhou YT et al. Lipopoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998; 273:32487-32490.

108. Pickersgill L, Litherland GJ, Greenberg AS et al. Key role for ceramides in mediating insulin resistance in human muscle cells. J Biol Chem 2007; 282:12583-12589.
109. Perry DK, Carton J, Shah AK et al. Serine Palmitoyltransferase Regulates de Novo Ceramide Generation during Epoxyeicosatrienoic Acid-Induced Apoptosis. J Biol Chem 2000; 275:9078-9084.

110. Bose R, Verheij M, Haimovitz-Friedman A et al. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 1995; 82:405-414.

111. Schissel SL, Tweedie-Hardman J, Rapp JH et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98:1455-1464.

112. Walters MJ, Wrenn SP. Effect of sphingomyelinase-mediated generation of ceramide on aggregation of low-density lipoprotein. Langmuir 2008; 24:9642-9647.

113. Boyanova SB, Karakashian A, King K et al. Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells: implications for the regulation of apoptosis. J Biol Chem 2003; 278:26992-26999.

114. Holland WL, Summers SA. Sphingolipids, Insulin Resistance and Metabolic Disease: New Insights from In Vivo Manipulation of Sphingolipid Metabolism. Endocr Rev 2008; 29:381-402.

115. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide Generation Is Sufficient to Account for the Inhibition of the Insulin-stimulated PKB Pathway in C2C12 Skeletal Muscle Cells Pretreated with Palmitate. J Biol Chem 1999; 274:24202-24210.

116. Xu J, Yeh CH, Chen S et al. Involvement of de Novo Ceramide Biosynthesis in Tumor Necrosis Factor-alpha/Cyclooxygenase-2-Induced Cerebral Endothelial Cell Death. J Biol Chem 1998; 273:16521-16526.

117. Garzotto M, White-Jones M, Jiang Y et al. 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LnCAP cells is mediated through ceramide synthase. Cancer Res 1998; 58:2260-2264.

118. Lehtonen JY, Horuchi M, Daviet L et al. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 1999; 274:16901-16906.

119. Guzman M, Galve-Roperh I, Sanchez C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 2001; 22:19-22.

120. Senkal CE, Ponnsamy S, Rossi MJ et al. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 2007; 6:712-722.

121. Petrache I, Natarajan V, Zhen L et al. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005; 11:491-498.

122. Park TS, Rosebury W, Kindt EK et al. Serine palmitoyltransferase inhibitor myricin induces the repression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol Res 2008; 58:45-51.

123. Cuzzocrea S, Deiginger HP, Genovese T et al. Inhibition of Ceramide Biosynthesis Ameliorates Pathological Consequences of Spinal Cord Injury. Shock 2008.

124. Guenther GG, Peralta ER, Rosales KR et al. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci USA 2008; 105:17402-17407.

125. Scarlatti F, Bauvy C, Venturini A et al. Ceramide-mediated Macrophagocytosis Involves Inhibition of Protein Kinase B and Up-regulation of Beclin 1. J Biol Chem 2004; 279:18384-18391.

126. Farrell AM, Uchida Y, Nagiec MM et al. UVB irradiation up-regulates serine palmitoyltransferase in cultured human keratinocytes. J Lipid Res 1998; 39:2031-2038.

127. Linn SC, Kim HS, Keane EM et al. Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochim Biophys Acta 2008; 1783:813-835.

128. Uhlinger DJ, Carton JM, Argentieri DC et al. Increased expression of serine palmitoyltransferase (SPT) in balloon-injured rat carotid artery. Thromb Haemost 2001; 86:1320-1326.

129. Min J, Mesika A, Sivaguru M et al. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 2007; 5:801-812.

130. Laviad EL, Albec P, Pankova-Kholymanksy I et al. Characterization of ceramide synthase 2: tissue distribution, substrate specificity and inhibition by sphingosine 1-phosphate. J Biol Chem 2008; 283:5677-5684.

131. Yabu T, Imamura S, Yamashita M et al. Identification of Mg2+-dependent neutral sphingomyelinate 1 as a mediator of stress-induced ceramide generation and apoptosis. J Biol Chem 2008; 283:29971-29982.

132. Marchesini N, Osta W, Bielawski J et al. Role for Mammalian Neutral Sphingomyelinase 2 in Confluence-induced Growth Arrest of MCF7 Cells. J Biol Chem 2004; 279:25101-25111.

133. Karakashian AA, Giltay NV, Smith GM et al. Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-1beta-induced JNK activation. FASEB J 2004; 18:968-970.

134. De Palma C, Meacci E, Perrotta C et al. Endothelial Nitric Oxide Synthase Activation by Tumor Necrosis Factor [alpha] Through Neutral Sphingomyelinase 2, Sphingosine Kinase 1 and Sphingosine 1 Phosphate Receptors: A Novel Pathway Relevant to the Pathophysiology of Endothelium. Arterioscler Thromb Vasc Biol 2006; 26:99-105.
Sphingolipids as Signaling and Regulatory Molecules

135. Shirakabe K, Yamaguchi K, Shibuya H et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-jun N-terminal kinase. J Biol Chem 1997; 272:8141-8144.
136. Verheij M, Bose R, Lin XH et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380:75-79.
137. Westwick JK, Bilawala AE, Dbaibo G et al. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995; 270:22689-22692.
138. Rurtkute K, Karakashian AA, Giltiay NV et al. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995; 270:22689-22692.
139. Tellier E, Negre-Salvayre A, Boquet B et al. Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway. Mol Cell Biol 2007; 27:2997-3007.
140. Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem 2007; 282:1384-1396.
141. Levade T, Malagarie-Cazenave S, Gouazé V et al. Ceramide in Apoptosis: A Revisited Role. Neurochemical Research 2002; 27:601-607.
142. Segui B, Cuvillier O, Adam-Klages S et al. Involvement of FAN in TNF-induced apoptosis. J Clin Invest 2001; 108:143-151.
143. Luberto C, Hassler DF, Signorelli P et al. Inhibition of Tumor Necrosis Factor-induced Cell Death in MCF7 by a Novel Inhibitor of Neutral Sphingomyelinase. J Biol Chem 2002; 277:41128-41139.
144. Corcoran CA, He Q, Ponnusamy S et al. Neutral sphingomyelinase-3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies. Mol Cancer Res 2008; 6:795-807.
145. Jayadhe S, Liu B, Bilawala AE et al. Role for ceramide in cell cycle arrest. J Biol Chem 1995; 270:2047-2052.
146. Hayashi Y, Kiyono T, Fujita M et al. cca1 Is Required for Formation of Growth-arrested Confluent Monolayer of Rat 3Y1 Cells. J Biol Chem 1997; 272:18082-18086.
147. Marchesini N, Luberto C, Hannun YA. Biochemical Properties of Mammalian Neutral Sphingomyelinase2 and Its Role in Sphingolipid Metabolism. J Biol Chem 2003; 278:13775-13783.
148. Nikolova-Karakashian M, Karakashian A, Rurtkute K. Role of neutral sphingomyelinas in aging and inflammation. Subcell biochem 2008; 49:469-486.
149. Rurtkute K, Asmis RH, Nikolova-Karakashian MN. Regulation of neutral sphingomyelinase-2 by GSH: a new insight to the role of oxidative stress in aging-associated inflammation. J Lipid Res 2007; 48:2443-2452.
150. Kim WJ, Okimoto RA, Purton LE et al. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 2008; 111:4716-4722.
151. Hayashi Y, Kiyono T, Fujita M et al. cca1 Is Required for Formation of Growth-arrested Confluent Monolayer of Rat 3Y1 Cells. J Biol Chem 1997; 272:18082-18086.
152. Goswami B, Ahmed M, Killus J et al. Differential regulation of ceramide in lipid-rich microdomains (rafts): Antagonistic role of palmitoyl:protein thioesterase and neutral sphingomyelinase 2. J Neurosci Res 2005; 81:208-217.
153. Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 1997; 272:16281-16287.
154. Gouaze V, Mirault ME, Carpentier S et al. Andrieu-Abadie. Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol 2001; 60:488-496.
155. Bello RI, Gomez-Diaz C, Buron MI et al. Enhanced anti-oxidant protection of liver membranes in long-lived rats fed on a coenzyme Q10-supplemented diet. Exp Gerontol 2005; 40:694-706.
156. Ayasola K, Khan M, Singh AK et al. Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E Free Radic Biol Med 2004; 37:325-338.
157. Castillo SS, Levy M, Thaikootattil JV et al. Reactive nitrogen and oxygen species activate different sphingomyelinas to induce apoptosis in airway epithelial cells. Exp Cell Res 2007; 313:2680-2686.
158. Martín SF, Sawai H, Villalba JM et al. Redox regulation of neutral sphingomyelinase-1 activity in HEK293 cells through a GSH-dependent mechanism. Arch Biochem Biophys 2007; 459:295-300.
159. Claus RA, Buncik AC, Bockmeyer CL et al. Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 2005; 19:1719-1721.
160. Wong ML, Xie B, Beatini N et al. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000; 97:8681-8686.
Ceramide in Stress Response

162. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene 22:7070-7077.
163. Santana P, Pena LA, Haimowitz-Friedman A et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86:189-199.
164. Morita Y, Tilly JL. Sphingolipid regulation of female gonadal cell apoptosis. Ann N Y Acad Sci 2000; 905:209-220.
165. Pena LA, Fuks Z, Kolesnick RN. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000; 60:321-327.
166. Cifone MG, De Maria R, Roncaillo P et al. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 1994; 180:1547-1552.
167. Gulbins E, Bissonnette R, Mahboubi A et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunology 1995; 2:341-351.
168. Grassme H, Jekle A, Riehle A et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001; 276:20589-20596.
169. Cremesti A, Paris F, Grassme H et al. Ceramide enables fas to cap and kill. J Biol Chem 2001; 276:23954-23961.
170. Utermohlen O, Herz J, Schramm M et al. Fusogenicity of membranes: the impact of acid sphingomyelinase on innate immune responses. Immunobiology 2008; 213:307-314.
171. Schramm M, Herz J, Haas A et al. Utermohlen. Acid sphingomyelinase is required for efficient phago-lysosomal fusion. Cell Microbiol 2008; 10:1839-1853.
172. Ng CG, Griffin DE. Acid sphingomyelinase deficiency increases susceptibility to fatal alphavirus encephalitis. J Virol 2006; 80:10989-10999.
173. Vit JP, Rosselli F. Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene 2003; 22:8645-8652.
174. Kroesen BJ, Jacobs S, Petrus BJ et al. BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J Biol Chem 2003; 278:14723-14731.
175. Wiegmann K, Sch, tze S, Machleidt T et al. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994; 78:1005-1015.
176. Bourbon NA, Sandirasegarane L, Kester M. Ceramide-induced Inhibition of Akt Is Mediated through Protein Kinase Czeta. Implications for Growth Arrest. J Biol Chem, 2002; 277:3286-3292.
177. Summers SA, Garza LA, Zhou H et al. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 1998; 18:5457-5464.
178. Powell DJ, Hajducz E, Kular G et al. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003; 23:7794-7808.
179. Fox TE, Housck KL, O'Neill SM et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem 2007; 282:12450-12457.
180. Wang G, Silva J, Krishnamurthy K et al. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J Biol Chem 2009; 284:26415-26424.
181. Petrus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002; 1585:114-125.
182. Heinrich M, Wickel M, Schneider-Brachert W et al. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J 1999; 18:5252-5263.
183. Heinrich M, Neumeyer J, Jakob M et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ 2004; 11:550-563.
184. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine and sphingosine-1-phosphate in programmed cell death. Biochem Biophys Acta 2006; 1758:2027-2036.
185. Sawada M, Nakashima S, Banno Y et al. Ordering of ceramide formation, caspase activation and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ 2000; 7:761-772.
186. Ito T, Deng X, Carr B et al. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272:11671-11673.
187. Chalfant CE, Rathman K, Pinkerman RL et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002; 277:12587-12595.
188. Sawada M, Kiyono T, Nakashima S et al. Molecular mechanisms of TNF-[alpha]-induced ceramide formation in human glioma cells:F53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ 2004; 11:997-1008.
189. Tepper AD, de Vries E, van Blitterswijk WJ et al. Ordering of ceramide formation, caspase activation and mitochondrial changes during CD95- and DNA damage-induced apoptosis. J Clin Invest 1999; 103:971-978.

190. Kashkar H, Wiegmann K, Yazdanpanah B et al. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 2005; 280:20804-20813.

191. Birbes H, Luberto C, Hsu YT et al. A mitochondrial pool of sphingomyelin is involved in TNFalpha-induced Bax translocation to mitochondria. Biochem J 2005; 386:445-451.

192. Rotolo JA, Zhang J, Donepudi M et al. Caspase-dependent and -independent Activation of Acid Sphingomyelinase Signaling. J Biol Chem 2005; 280:26425-26434.

193. Dbaibo GS, Pushkareva MY, Jayadev S et al. Retinoblastoma. J Cell Physiol 2000; 184:285-300.

194. Lee JY, Bielawski AE, Obeid LM. Regulation of Cyclin-Dependent Kinase 2 Activity by Ceramide. Exp Cell Res 2000; 261:303-311.

195. Venable ME, Bielawski A, Obeid LM. Ceramide Inhibits Phospholipase D in a Cell-free System. J Biol Chem 1996; 271:24800-24805.

196. Lee JY, Hannun YA, Obeid LM. Ceramide Inactivates Cellular Protein Kinase Calpha. J Biol Chem 1996; 271:13169-13174.

197. Westwick JK, Bielawski AE, Dbaibo G et al. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995; 270:22689-22692.

198. Lattis KM, Koretzky GA. Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T-cells. Blood 1996; 87:871-875.

199. Verheij M, Bose R, Lin YH et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380:75-79.

200. Brenner B, Koppenhoefer U, Weinstock C et al. Fas- or Ceramide-induced Apoptosis Is Mediated by a Rac-1-regulated Activation of Jun N-terminal Kinase/p38 Kinases and GADD153. J Biol Chem 1997; 272:22173-22181.

201. Bourbon NA, Yun J, Kester M. Ceramide Directly Activates Protein Kinase C zeta to Regulate a Stress-activated Protein Kinase Signaling Complex. J Biol Chem 2000; 275:35617-35623.

202. Shirakabe K, Yamaguchi K, Shibuya H et al. TAK1 Mediates the Ceramide Signaling to Stress-activated Protein Kinase/c-Jun N-terminal Kinase. J Biol Chem 1997; 272:8141-8144.

203. Strle K, Broussard SR, McCusker RH et al. C-Jun N-terminal kinase mediates tumor necrosis factor-alpha suppression of differentiation in myoblasts. Endocrinology 2006; 147:4363-4373.

204. Rutkute K, Nikolova-Karakashian MN. Regulation of insulin-like growth factor binding protein-1 expression during aging. Biochem Biophys Res Commun 2007; 361:263-269.

205. Chen S, Lee JM, Zeng C et al. Amyloid beta peptide increases DPF expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J Neurochem 2006; 97:631-640.

206. Kolesnick RN, Goni FM, Alonso A. Compartmentalization of ceramide signaling: physical foundations and biological effects. J Cell Physiol 2000; 184:285-300.

207. Gulbins E, Li PL. Physiological and pathophysiological aspects of ceramide. AJP—Regulatory, Integrative and Comparative Physiology 2006; 290: R11-26.

208. Miyaji M, Jin ZX, Yamaoka S et al. Okazaki and H. Umehara. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 2005; 202:249-259.

209. Siskind LJ, Kolesnick RN, Colombini M. Ceramide Channels Increase the Permeability of the Mitochondrial Outer Membrane to Small Proteins. J Biol Chem 2002; 277:26796-26803.

210. Choudhury A, Sharma DK, Marks DL et al. Elevated endosomal cholesterol levels in Niemann-Pick cells inhibit rab1 and perturb membrane recycling. Mol Biol Cell 2004; 15:4500-4511.

211. Uterm‘hlen O, Herz J, Schramm M et al. Fusogenicity of membranes: The impact of acid sphingomyelinase on innate immune responses. Immunobiology 2008; 213:307-314.

212. Merrill AH Jr, Jones DD. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta 1990; 1044:1-12.